The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| HJLI | -87.35% | -96.37% | -48.45% | -100% |
| S&P | +16.49% | +84.25% | +12.99% | +153% |
enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. Its products include The Bioprosthetic Heart Valve, The CoreoGraft, and The Venous Valve. The company was founded by Norman Jaffe on December 22, 1999 and is headquartered in Irvine, CA.
No news articles found for enVVeno Medical.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$120.00K | 7.0% |
| Market Cap | $17.44M | -61.1% |
| Market Cap / Employee | $471.35K | 0.0% |
| Employees | 37 | 19.4% |
| Net Income | -$4,539.00K | 19.5% |
| EBITDA | -$4,763.00K | 21.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.54M | -91.4% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $505.00K | -36.2% |
| Short Term Debt | $286.00K | -19.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -53.09% | 1.0% |
| Return On Invested Capital | -63.17% | 87.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4,392.00K | -2.5% |
| Operating Free Cash Flow | -$4,392.00K | -2.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.12 | 1.09 | 1.83 | 0.53 | -54.74% |
| Price to Tangible Book Value | 1.12 | 1.09 | 1.83 | 0.53 | -54.74% |
| Enterprise Value to EBITDA | -1.65 | -3.22 | -6.78 | 2.50 | -323.44% |
| Return on Equity | -49.4% | -52.9% | -64.5% | -57.2% | -2.68% |
| Total Debt | $1.06M | $979.00K | $882.00K | $791.00K | -31.10% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
